Rare diseases
Investigational molecules
Locations
Phase 2 Study of Nemolizumab for Skin Thickening in Adults with Systemic Sclerosis
BulgariaPharmacokinetics, Safety and Efficacy of Nemolizumab in Infants 6–23 Months with Moderate-to-Severe Atopic Dermatitis
PolandAssessing the efficacy and safety of nemolizumab in patients aged 12 years or older with dystrophic epidermolysis bullosa
FranceStudy on the Long-Term Safety and Efficacy of Nemolizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis
AustriaStudy on the Long-Term Safety and Effectiveness of Nemolizumab for Patients with Prurigo Nodularis
AustriaStudy on Nemolizumab for Children Aged 2-11 with Moderate-to-Severe Atopic Dermatitis Not Controlled by Topical Treatments
HungaryTell us about your condition – we search every trial in Europe and connect you with the right site.
